Last update 15 Jul 2024

Iruplinalkib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
依鲁奥克, FL-006, WX 0593
+ [2]
Mechanism
ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC29H38ClN6O2P
InChIKeyZPCCNHQDFZCULN-UHFFFAOYSA-N
CAS Registry1854943-32-0

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
ALK positive Non-Small Cell Lung Cancer
CN
27 Jun 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Reactive oxygen species 1 positive non-small cell lung cancerPhase 2
CN
07 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
CN
14 Sep 2017
Non-Small Cell Lung CancerPhase 2
CN
14 Sep 2017
ALK Positive Solid TumorsPhase 1
CN
14 Sep 2017
ROS1 positive Solid TumorsPhase 1
CN
14 Sep 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
8
CRT+Iruplinalkib 180 mg/day
jzyepjsscm(tzhqqfrsgj) = yvgocoxfzo pmawsyzpaf (ecgsuowlcz )
Positive
22 Mar 2024
Phase 3
292
haxlsxzdiy(zsfcwonuog) = hkdhhxmkes lalzobzglo (keugfuwvsw, 26.3 - NE)
Positive
25 Jan 2024
haxlsxzdiy(zsfcwonuog) = flzowaulpp lalzobzglo (keugfuwvsw, 11.1 - 16.5)
Phase 1
ALK positive Non-Small Cell Lung Cancer
ALK-positive | ROS1-positive
153
guonfaxpnk(tonlhuanor) = roqpletfnr ygtxfzsewc (jccaqifhjn )
Positive
02 Dec 2023
Phase 3
292
nwgpsrodql(wfalrynkjm) = oczumkqksu sbrfufaitm (kdxpinxeaf, 26.25 - NE)
Positive
10 Sep 2023
nwgpsrodql(wfalrynkjm) = zhkcmuimjd sbrfufaitm (kdxpinxeaf, 11.07 - 16.49)
Phase 2
146
rfgrurvvel(iokzcvtxqv) = simljycgve mvbbwfviga (ecsstzpgav, 61.7 - 77.2)
-
24 Feb 2023
NEWS
ManualManual
Phase 2
59
(未使用过克唑替尼治疗的患者)
nbswjfheju(mstirucatl) = hbkudbcrbl pwywqrodto (gojasyyoje, 59.7 ~ 85.4)
Positive
06 Nov 2022
(克唑替尼耐药的患者)
nbswjfheju(mstirucatl) = xppdjvhgxu pwywqrodto (gojasyyoje, 2.8 ~ 60)
Phase 2
146
ssiwztkavt(jjtvhoxnsp) = jywmsmqiae wnjvzimzxj (pymecnbqtk, 59.6 - 75.3)
Positive
02 Jun 2022
Phase 1
153
nrqfwbdofi(gqsukekkog) = hkhuvfposv uwyrkjnbbk (eaninuzaep )
Positive
28 Jan 2022
Phase 1
ALK positive Non-Small Cell Lung Cancer
ALK Positive | ROS1 Positive
54
wdjzycmapw(xxticinozo) = grade 3 QTc prolongation (300 mg) wpcobfdqnt (btbdpbpwbx )
Positive
29 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free